文献速递乳房整形与再造显微修复重建创面修复

DIEP皮瓣联合淋巴外科优化乳腺癌相关淋巴水肿生活质量

Optimizing Quality of Life for Patients with Breast Cancer-Related Lymphedema: A Prospective Study Combining DIEP Flap Breast Reconstruction and Lymphedema Surgery.
PubMed 文献 · Plast Reconstr Surg · 2020-01-01

联合组主观症状改善率100%,显著高于单纯组的81.0%(p=0.019);早期周径测量改善显著,但12个月时差异无统计学意义。结论认为联合手术安全有效,可能优于单纯淋巴结移植。

要点

  • 联合组主观症状改善率100%,显著高于单纯淋巴结移植组的81.0%(p=0.019)。
  • 3个月和6个月周径测量改善联合组显著优于单纯组,12个月时差异不显著。
  • 联合手术为DIEP皮瓣+血管化腹股沟淋巴结移植+淋巴静脉吻合,平均每例2个吻合。

核心结论

  • DIEP皮瓣联合血管化腹股沟淋巴结移植与淋巴静脉吻合安全有效,可能优于单纯淋巴结移植。
  • 联合组主观症状改善率显著高于单纯淋巴结移植组(100% vs 81.0%,p=0.019)。

研究设计与样本

  • 两组在人口学、辅助化疗或放疗方面无显著差异,平均切除淋巴结数相当(21.2 vs 21.4)。

主要发现

  • 联合组所有患者(100%)报告主观症状改善,单纯组为81.0%(p=0.019)。
  • 周径测量显示3个月改善率联合组40.7% vs 单纯组20.0%(p=0.037)。
  • 6个月改善率联合组57.0% vs 单纯组44.5%(p=0.043)。
  • 12个月改善率联合组60.4% vs 单纯组57.8%(p=0.43),差异无统计学意义。
  • 联合组平均每例完成2个淋巴静脉吻合(范围1–4个)。

关键数值与推荐

  • 联合组主观症状改善率100%,单纯组81.0%(p=0.019)。
  • 3个月周径改善率40.7% vs 20.0%(p=0.037);6个月57.0% vs 44.5%(p=0.043)。
  • 12个月周径改善率60.4% vs 57.8%(p=0.43)。

临床怎么用

  • 对乳腺癌相关淋巴水肿患者,可考虑DIEP皮瓣重建同期联合血管化腹股沟淋巴结移植及淋巴静脉吻合。
  • 联合手术在早期(3–6个月)淋巴水肿改善上可能优于单纯淋巴结移植,但12个月时优势不显著。

局限性

  • 联合组为前瞻性随访,单纯组为回顾性队列,存在设计差异。
  • 12个月时周径测量差异无统计学意义,长期优势需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with breast cancer-related lymphedema can be treated with a simultaneous deep inferior epigastric perforator (DIEP) flap, vascularized inguinal lymph node transfer, and lymphovenous anastomosis for aesthetic breast reconstruction and lymphedema in one operation. METHODS: The authors performed a comparison of prospectively followed patients who underwent free flap breast reconstruction with vascularized inguinal lymph node transfer and anastomosis to a retrospective cohort of patients who underwent free flap breast reconstruction with vascularized inguinal lymph node transfer alone. RESULTS: Thirty-three patients underwent DIEP flap reconstruction with vascularized inguinal lymph node transfer and lymphovenous anastomosis, and 21 received a free flap with lymph node transfer alone. There were no significant differences in demographics, adjuvant chemotherapy, or radiation therapy. The average number of nodes removed was also equivalent (21.2 versus 21.4 nodes). Two anastomoses per patient, on average, were performed (range, one to four) in the combined cohort, and all patients (100 percent) reported a subjective improvement in symptoms, compared with 81.0 percent of patients undergoing only lymph node transfer (p = 0.019). Perometer measurements demonstrated a significant reduction between the groups at early time points [3 months, 40.7 percent versus 20.0 percent (p = 0.037); 6 months, 57.0 percent versus 44.5 percent (p = 0.043)]; however, the difference was not statistically significant at 12 months (60.4 percent versus 57.8 percent; p = 0.43). CONCLUSION: This is the first prospective study demonstrating the safety and efficacy of a combined DIEP flap with vascularized inguinal lymph node transfer and lymphovenous anastomosis, which may be superior to lymph node transfer alone. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Chang EI, Ibrahim A, Liu J, et al. Optimizing Quality of Life for Patients with Breast Cancer-Related Lymphedema: A Prospective Study Combining DIEP Flap Breast Reconstruction and Lymphedema Surgery. Plast Reconstr Surg. 2020. PMID: 32221193. doi:10.1097/PRS.0000000000006634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。